Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Keratinocyte-derived cytokine TSLP promotes growth and metastasis of melanoma by regulating the tumor-associated immune microenvironment
Wenjin Yao, Beatriz German, Dounia Chraa, Antoine Braud, Cecile Hugel, Pierre Meyer, Guillaume Davidson, Patrick Laurette, Gabrielle Mengus, Eric Flatter, Pierre Marschall, Justine Segaud, Marine Guivarch, Pierre Hener, Marie-Christine Birling, Dan Lipsker, Irwin Davidson, Mei Li
Wenjin Yao, Beatriz German, Dounia Chraa, Antoine Braud, Cecile Hugel, Pierre Meyer, Guillaume Davidson, Patrick Laurette, Gabrielle Mengus, Eric Flatter, Pierre Marschall, Justine Segaud, Marine Guivarch, Pierre Hener, Marie-Christine Birling, Dan Lipsker, Irwin Davidson, Mei Li
View: Text | PDF
Research Article Dermatology Oncology

Keratinocyte-derived cytokine TSLP promotes growth and metastasis of melanoma by regulating the tumor-associated immune microenvironment

  • Text
  • PDF
Abstract

Malignant melanoma is a major public health issue displaying frequent resistance to targeted therapy and immunotherapy. A major challenge lies in better understanding how melanoma cells evade immune elimination and how tumor growth and metastasis is facilitated by the tumor microenvironment. Here, we show that expression of the cytokine thymic stromal lymphopoietin (TSLP) by epidermal keratinocytes is induced by cutaneous melanoma in both mice and humans. Using genetically engineered models of melanoma and tumor cell grafting combined with TSLP-KO or overexpression, we defined a crosstalk between melanoma cells, keratinocytes, and immune cells in establishing a tumor-promoting microenvironment. Keratinocyte-derived TSLP is induced by signals derived from melanoma cells and subsequently acts via immune cells to promote melanoma progression and metastasis. Furthermore, we show that TSLP signals through TSLP receptor–expressing (TSLPR-expressing) DCs to play an unrecognized role in promoting GATA3+ Tregs expressing a gene signature including ST2, CCR8, ICOS, PD-1, CTLA-4, and OX40 and exhibiting a potent suppressive activity on CD8+ T cell proliferation and IFN-γ production. An analogous population of GATA3-expressing Tregs was also identified in human melanoma tumors. Our study provides insights into the role of TSLP in programming a protumoral immune microenvironment in cutaneous melanoma.

Authors

Wenjin Yao, Beatriz German, Dounia Chraa, Antoine Braud, Cecile Hugel, Pierre Meyer, Guillaume Davidson, Patrick Laurette, Gabrielle Mengus, Eric Flatter, Pierre Marschall, Justine Segaud, Marine Guivarch, Pierre Hener, Marie-Christine Birling, Dan Lipsker, Irwin Davidson, Mei Li

×

Figure 1

Keratinocyte-derived TSLP promotes growth and metastasis of Braf/Pten melanoma.

Options: View larger image (or click on image) Download as PowerPoint
Keratinocyte-derived TSLP promotes growth and metastasis of Braf/Pten me...
(A–C) Epidermal TSLP expression is induced during melanomagenesis in Braf/Pten mice. (A) Ear and ear-draining lymph nodes (ELN) appearance of Tyr:CreERT2(tg/0) BrafLSL–V600E/+ Ptenlox/lox mice injected i.p. with tamoxifen (Braf/Pten mice). (B) Kinetic of TSLP protein levels in ears (left panel) and dorsal melanoma (right panel) from Braf/Pten mice, compared with ears and dorsal skin from control (CT, Tamoxifen-injected Tyr:CreERT2(0/0) BrafLSL–V600E/+ Ptenlox/lox) littermates. Data are shown as mean ± SEM. n = 5 for all groups, except n = 4 for Braf/Pten dorsal tumors and CT dorsal skin at D49. (C) RNAScope ISH for TSLP mRNA on paraffin sections. Black arrows point to one of the positive signals in the epidermis (in red). Scale bar: 50 μm. (D–I) Ablation of TSLP delays melanoma growth and metastasis. (D) Ear appearance of Braf/Pten/Tslp+/+ and Braf/Pten/Tslp–/– mice at D30 and D35 following topical 4-hydroxytamoxifen (4-HT) treatment. (E and F) H&E staining (E) and IHC staining of SOX10 (F) of sections from ears at D30. Blue arrows points to one of the positive signals (in dark red). Scale bar: 50 μm. (G) Comparison of volumes of solid tumors developed in mice at the indicated time points. Data are shown as mean ± SEM. Student’s t test. **P < 0.01. n = 11 (Braf/Pten/Tslp+/+) and n = 10 (Braf/Pten/Tslp–/–). (H) Appearance of ELNs and dorsal tumor-draining inguinal lymph nodes (ILNs) at D41. (I) IHC staining of Sox10 on ILN sections at D41. Blue arrow points to one of the positive signals (in dark red). Scale bar: 50 μm. Data are representative of 3 independent experiments with similar results.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts